Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for genetically defined diseases. Founded in 2016, Fulcrum has made significant strides in the industry, particularly in the field of rare genetic disorders. The company is renowned for its unique approach to drug development, leveraging its proprietary gene modulation platform to create targeted treatments. Fulcrum's lead product candidates aim to address unmet medical needs, setting the company apart in a competitive market. With a commitment to advancing science and improving patient outcomes, Fulcrum Therapeutics has established itself as a key player in the biopharmaceutical landscape, continually striving for excellence in the pursuit of transformative therapies.
DitchCarbon Score
How does Fulcrum Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fulcrum Therapeutics, Inc.'s score of 18 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Fulcrum Therapeutics, Inc.'s reported carbon emissions
Fulcrum Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. As such, there are no reported figures for their Scope 1, 2, or 3 emissions. The company has not outlined any formal climate commitments or initiatives aimed at reducing carbon emissions. In the absence of specific data, it is essential to monitor their future sustainability efforts and commitments within the biopharmaceutical industry, which increasingly prioritises environmental responsibility.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fulcrum Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
